Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 2.00 -0.73 (26.74%)
Day High: 2.47
Day Low:  1.85
Volume:    7,521,506
4:00 PM ET
Sep 29, 2016

Delayed ~20 min., by eSignal.